Fabrice Le Boeuf

List of Publications by Year in Descending Order

38 papers	3,008 citations	23 h-index	38 g-index
38 ext. papers	3,382 ext. citations	11.6 avg, IF	4.73 L-index

#	Paper	IF	Citations
38	Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. *Molecular Therapy - Oncolytics*, **2020**, 17, 232-240	6.4	18
37	Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. *Molecular Therapy - Oncolytics*, **2019**, 14, 246-252	6.4	9
36	Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis. *PLoS Pathogens*, **2018**, 14, e1007264	7.6	11
35	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. *OncoImmunology*, **2018**, 7, e1503032	7.2	50
34	Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds. *Molecular Therapy*, **2018**, 26, 56-69	11.7	55
33	Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. *OncoImmunology*, **2018**, 7, e1407897	7.2	20
32	Development and applications of oncolytic Maraba virus vaccines. *Oncolytic Virotherapy*, **2018**, 7, 117-128	8	24
31	Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma. *International Journal of Cancer*, **2017**, 141, 1257-1264	7.5	23
30	The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses. *Oncolytic Virotherapy*, **2017**, 7, 25-35	6	5
29	Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models. *Molecular Therapy - Oncolytics*, **2017**, 6, 80-89	6.4	26
28	Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors. *Journal of Nuclear Medicine*, **2017**, 58, 221-227	8.9	17
27	First-in-class small molecule potentiators of cancer virotherapy. *Scientific Reports*, **2016**, 6, 26786	4.9	21
26	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. *Molecular Therapy - Oncolytics*, **2016**, 3, 16027	6.4	9
25	Single-particle characterization of oncolytic vaccinia virus by flow virometry. *Vaccine*, **2016**, 34, 5082-5089	4.1	19
24	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. *Cancer Cell*, **2015**, 28, 210-24	24.3	62
23	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. *Nature Communications*, **2015**, 6, 6410	17.4	36
22	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. *Nature Medicine*, **2015**, 21, 530-6	50.5	93

21	Smac mimetics and innate immune stimuli synergize to promote tumor death. *Nature Biotechnology*, **2014**, 32, 182-90	44.5	92
20	Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. *Molecular Therapy*, **2014**, 22, 1188-1197	11.7	27
19	High-throughput titration of luciferase-expressing recombinant viruses. *Journal of Visualized Experiments*, **2014**, 51890	1.6	6
18	Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. *International Journal of Cancer*, **2013**, 132, 726-31	7.5	10
17	Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. *Journal of Virology*, **2013**, 87, 2363-6	6.6	15
16	Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. *Clinical Cancer Research*, **2013**, 19, 3832-43	12.9	23
15	Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. *Molecular Therapy*, **2012**, 20, 1791-9	11.7	56
14	Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. *International Journal of Cancer*, **2012**, 131, E204-15	7.5	13
13	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. *Molecular Therapy*, **2012**, 20, 749-58	11.7	177
12	Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. *Methods in Molecular Biology*, **2012**, 797, 127-40	1.4	27
11	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature*, **2011**, 477, 99-102	50.4	392
10	Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. *Journal of Virology*, **2010**, 84, 856-66	6.6	46
9	Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. *Molecular Therapy*, **2010**, 18, 896-902	11.7	25
8	A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. *Molecular Therapy*, **2010**, 18, 1123-9	11.7	67
7	Synergistic interaction between oncolytic viruses augments tumor killing. *Molecular Therapy*, **2010**, 18, 888-95	11.7	97
6	United virus: the oncolytic tag-team against cancer!. *Cytokine and Growth Factor Reviews*, **2010**, 21, 205-11	17.9	14
5	Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. *PLoS ONE*, **2010**, 5, e14462	3.7	54
4	Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. *Molecular Biology of the Cell*, **2007**, 18, 4659-68	3.5	123

3	Endothelial cell migration during angiogenesis. *Circulation Research*, **2007**, 100, 782-94	15.7	978
2	Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. *PLoS Medicine*, **2007**, 4, e353	11.6	154
1	Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. *Journal of Biological Chemistry*, **2004**, 279, 39175-85	5.4	114